Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Quarck, E. Ninio, H. Durand, W. Daenen, D. Marion (Leuven, Belgium; Paris, France). Platelet-activating factor-acetylhydrolase (PAF-AH) activity in pulmonary arterial hypertension (PAH). Eur Respir J 2005; 26: Suppl. 49, 4429

Member's Comments

No comment yet.

Related content which might interest you: Could platelet-activating factor acetylhydrolase (PAF-AH) predict adverse event in pulmonary hypertension? Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 C-reactive protein and platelet-activating factor-acetylhydrolase activity: new predictors of outcome in pulmonary hypertension Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH) Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010 Platelets and pulmonary arterial hypertension (PAH) Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017 Regulation of inflammation process in chronic thromboembolic pulmonary hypertension: a potential role of platelet-activating factor-acetylhydrolase Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Expression of platelet derived-growth factor (PDGF) in remodelled pulmonary arteries of COPD patients Source: Eur Respir J 2002; 20: Suppl. 38, 25s Year: 2002 Arterial hypertension (AH) and endothelial function (EF) in patients with COPD Source: Annual Congress 2011 - COPD mechanisms Year: 2011 Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Atrial natriuretic peptide plasma concentration (ANP) and pulmonary hemodynamics (HEMO) after acute nitric oxide inhalation (NO) in patients with connective tissue disease and pulmonary artery hypertension (CTDPH) Source: Eur Respir J 2005; 26: Suppl. 49, 561s Year: 2005 Dual mechanism of platelet-derived growth factor (PDGF)-receptor: Contribution of vascular response to the pathogenesis of pulmonary hypertension (PH) Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Early atorvastatin administration suppresses the oxygen-activating ability of rat neutrophils during monocrotalinin-induced pulmonary arterial hypertension (PAH). Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 High-altitude pulmonary hypertension Source: Eur Respir Rev 2009; 18: 13-17 Year: 2009 Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 881-891 Year: 2008 Pharmacologic characterization of GB002, a novel inhaled PDGFR kinase inhibitor in development for pulmonary arterial hypertension (PAH) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH) Source: Eur Respir J 2004; 24: Suppl. 48, 109s Year: 2004 Monocyte chemotactic protein-1 (MCP-1) synthesis and function in pulmonary artery smooth muscle cells (PA-SMCs) from patients with idiopathic pulmonary hypertension (IPH) Source: Eur Respir J 2004; 24: Suppl. 48, 436s Year: 2004 Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012